Program
Risperidone
Also written as “risperidone”, “Oral risperidone” and “Risperidone ISM 100 mg”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Psychotic Disorders · Autistic Disorder · Dementia, led by 15 companies.
Drug pageRisperidone: every studyMany companies study it; this page follows only the 99 they lead. All 262 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 670 open or running | phase 4since Jun 4, 2003 | May 2, 2002 | none ahead |
| Rovi Pharmaceuticals Laboratories | 50 open or running | phase 3since May 12, 2017 | Feb 5, 2013 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 3since Apr 9, 2018 | Jan 26, 2009 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 4since Nov 14, 2005 | May 2, 2002 | none ahead |
| Luye Pharma Groupits history only | 30 open or running | phase 1since Jan 31, 2014 | Jan 31, 2014 | none ahead |
| Lyndraits history only | 30 open or running | phase 3since Mar 9, 2023 | Sep 16, 2020 | none ahead |
| Braeburn Pharmaceuticalsits history only | 20 open or running | phase 3since May 11, 2016 | Jan 7, 2016 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Feb 4, 2010 | Feb 4, 2010 | none ahead |
| IPCA Laboratoriesits history only | 20 open or running | phase 1since Jun 11, 2012 | Jun 11, 2012 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Oct 15, 2010 | Oct 15, 2010 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 10, 2009 | Jul 10, 2009 | none ahead |
| Delporits history only | 10 open or running | phase 2since Jun 1, 2020 | Jun 1, 2020 | none ahead |
| Indivior Pharmaceuticalsits history only | 10 open or running | phase 4since May 30, 2019 | May 30, 2019 | none ahead |
| Pfizerits history only | 10 open or running | no phasesince Sep 9, 2005 | Sep 9, 2005 | none ahead |
| Yung Shin Pharm. Ind.its history only | 10 open or running | phase 2since Oct 23, 2023 | Oct 23, 2023 | none ahead |
Also a collaborator on its studies: Otsuka and H. Lundbeck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Rovi Pharmaceuticals Laboratories only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2013First study: phase 1 study in SchizophreniaFirst studyNCT01788774 · 36 enrolled · Croatia, Russian Federation, South Africa and more
- May 12, 2017Phase 3 study in Acute SchizophreniaNCT03160521 · 438 enrolled · United States, Ukraine
- May 4, 2018Phase 1 study in SchizophreniaNCT03527186 · 81 enrolled · United States
- Feb 26, 2019Phase 3 study in SchizophreniaNCT03870880 · 215 enrolled · United States, Ukraine
- Dec 16, 2021Phase 1 study in SchizophreniaNCT05179525 · 80 enrolled · United States
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
Studies
All 5 Rovi Pharmaceuticals Laboratories leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05179525Schizophrenia · United States | 1 | Completed | Sep 17, 2021 | 80 |
| NCT03870880Schizophrenia · United States, Ukraine | 3 | Completed | Jan 8, 2020 | 215 |
| NCT03527186Schizophrenia · United States | 1 | Completed | Mar 23, 2019 | 81 |
| NCT03160521Acute Schizophrenia · United States, Ukraine | 3 | Completed | Dec 17, 2018 | 438 |
| NCT01788774Schizophrenia · Croatia, Russian Federation, South Africa and more | 1 | Completed | Feb 2014 | 36 |
How it is read
Names in the registry
- “risperidone”, 40 entries
- “Risperidone”, 34 entries
- “Oral risperidone”, 5 entries
- “Risperidone ISM 100 mg”, 3 entries
- “LY03004”, 3 entries
Codes read as this program: LYN005.
Conditions, from the studies’ own filings
- Schizophrenia, 63 studies
- Bipolar Disorder, 12 studies
- Psychotic Disorders, 3 studies
- Autistic Disorder, 3 studies
- Dementia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.